Susana N. Banerjee
Royal Marsden NHS Foundation Trust · 642 works · 30,806 citations · h-index 68
Top works
- Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
- Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
- Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
- ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up
- ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
- Basal-like breast carcinomas: clinical outcome and response to chemotherapy
- Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial
- Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial
- Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer
- LBA70_PR The impact of COVID-19 on oncology professionals: Initial results of the ESMO resilience task force survey collaboration
- Clinical Activity and Safety of the Anti–Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair–Deficient Endometrial Cancer
- Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer
- Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial
- PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline
- Global cancer control: responding to the growing burden, rising costs and inequalities in access
- New Strategies in the Treatment of Ovarian Cancer: Current Clinical Perspectives and Future Potential
- Exploiting the folate receptor α in oncology
- ESGO–ESMO–ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease
- Postmenopausal endogenous oestrogens and risk of endometrial cancer: results of a prospective study
- Professional burnout in European young oncologists: results of the European Society for Medical Oncology (ESMO) Young Oncologists Committee Burnout Survey